logo
U.S. to Dump Billions of Flies From Planes to Fight ‘Man-Eater' Maggots

U.S. to Dump Billions of Flies From Planes to Fight ‘Man-Eater' Maggots

Gizmodo03-07-2025
The U.S. The Department of Agriculture has declared war on a flesh-eating maggot that infests wildlife, livestock, household pets, and, in rare cases, people. The battle strategy? Dumping billions of sterilized flies out of planes over Mexico and Texas.
Using this tried-and-true biological control technique, the USDA aims to stamp out the larvae of the New World screwworm (NWS) fly, a tropical parasite. This invasive pest's scientific name is Cochliomyia hominivorax, which literally means 'man-eater.' The flies target warm-blooded animals, laying eggs near open wounds and mucous membranes, according to the Texas Farm Bureau. When the eggs hatch, the maggots burrow deep into the host's living tissue, eating it as they grow and causing painful, potentially deadly wounds. If the NWS fly spreads throughout the U.S., it could decimate the livestock industry, kill wild animals in droves, and pose a significant risk to pet and human health.
'A thousand-pound bovine can be dead from this in two weeks,' Michael Bailey, president-elect of the American Veterinary Medicine Association, told the Associated Press.
To eliminate this pest, USDA scientists are breeding adult male NWS flies and sterilizing them with radiation before releasing them from aircraft. When these flies mate with females, the eggs they produce won't hatch, thus reducing the number of maggots and causing the population to die out over time. This approach is more environmentally friendly than pesticides, and while it may sound counterintuitive, it has worked in the past.
'The United States has defeated NWS before and we will do it again,' USDA Secretary Brooke Rollins said. From 1962 to 1974, the U.S. and Mexico released more than 94 billion sterile flies to eradicate the pest, according to the USDA. By 2000, the pest was contained below Panama thanks to a sterile fly facility there, though small outbreaks continued to occur in the U.S. occasionally, like the one that struck the Florida Keys in 2017.
'It's an exceptionally good technology,' Edwin Burgess, an assistant professor at the University of Florida who studies parasites in livestock, told the Associated Press. 'It's an all-time great in terms of translating science to solve some kind of large problem.'
Over the past several years, NWS fly populations south of the U.S. have expanded northward, according to the American Farm Bureau. Recent detections in Mexico as far north as Oaxaca and Veracruz—just 700 miles (1,127 kilometers) from the southern border—prompted U.S. officials to suspend cattle, horse, and bison imports through the border on May 11.
On June 18, Rollins announced the development of an $8.5 million sterile NWS fly dispersal facility alongside an aggressive plan to prevent this pest from re-entering the U.S. The fly factory, located at Moore Air Base in south Texas, should be complete by the end of the year. It could boost domestic sterile fly production by up to 300 million flies per week, complementing current facilities already operating in Panama and Mexico. The USDA has also invested $21 million toward renovating an existing fly factory in Metapa, Mexico, which will provide an additional 60 to 100 million sterile NWS flies per week to stop the spread. On top of Panama's production, this will release at least 160 million flies in Mexico and Panama per week, the USDA states.
The first weeks of this NWS fly attack strategy have already shown results. Since officials closed southern ports to livestock in May, the USDA has dispersed more than 100 million sterile NWS flies per week in Mexico, according to a statement released Monday, June 30. The agency said it has not seen a notable increase in parasitic NWS infections in Mexico or any northward movement of this pest over the past eight weeks. Based on these findings, the USDA has decided to gradually reopen select southern border ports to livestock trade beginning July 7.
These are good signs that officials are regaining control of this pest. As the planet continues to warm, however, more invasive insects and parasites will creep northward from the tropics, threatening U.S. agriculture, biodiversity, and public health. As such, sterile fly breeding and distribution programs may become increasingly necessary. Burgess argues that officials should keep fly factories open even after they have neutralized the threat of NWS. 'Something we think we have complete control over—and we have declared a triumph and victory over—can always rear its ugly head again,' he said.
Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare
Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare

Yahoo

time17 minutes ago

  • Yahoo

Hims & Hers Leads the Charge in AI-Powered Personalized Healthcare

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, is building a next-generation, digital-first healthcare platform centered around personalization, accessibility and scalability. Its model integrates telehealth consultations, electronic medical records, cloud-based pharmacy fulfillment and artificial intelligence (AI)-driven care routing — creating a seamless end-to-end user experience across conditions like mental health, dermatology, sexual wellness and weight management. HIMS' subscription-based approach reached 2.4 million subscribers in first-quarter 2025, with over 1.4 million using personalized solutions, reflecting strong demand for tech-enabled care. Central to Hims & Hers' strategy is its expanding investment in AI. The recent appointment of Mo Elshenawy as chief technology officer (CTO) marks a pivotal move toward scaling intelligent, individualized care. Elshenawy brings over two decades of experience in AI, robotics and cloud infrastructure, and is tasked with enhancing diagnostics, automation and platform personalization. These efforts are supported by an $870 million upsized convertible notes offering, with proceeds earmarked for AI innovation and global expansion. Hims & Hers is also vertically integrating its operations through acquisitions in pharmacy and diagnostics, enabling greater control over fulfillment and care quality. Tools like MedMatch use data to route patients to the right care pathways, while new AI applications aim to automate and refine diagnosis and treatment recommendations. By blending direct-to-consumer infrastructure with advanced technology, Hims & Hers is enhancing healthcare delivery for millions — offering a scalable model that delivers high-quality, personalized care with efficiency. LFMD & DOCS' Digital-First Transformation LifeMD, Inc. LFMD has rapidly evolved into a comprehensive digital-first healthcare platform offering vertically integrated telehealth solutions. With LifeMD's nationwide physician network, proprietary electronic medical records and in-house pharmacy operations, it delivers personalized care at scale. LFMD supports recurring subscription models across multiple specialties, including weight management and primary care. LifeMD's tech-enabled ecosystem enhances clinical access, operational efficiency and long-term subscriber value through continuous innovation. Doximity, Inc. DOCS continues to redefine physician engagement through its digital-first strategy, offering HIPAA-compliant telehealth tools and AI-powered workflow enhancements. Doximity enables doctors to connect, consult and collaborate seamlessly within its professional network. DOCS' platform integrates secure messaging, eFax and personalized newsfeeds, reflecting Doximity's mission to streamline clinical operations and empower providers with intelligent, scalable solutions. HIMS' Price Performance, Valuation and Estimates Shares of Hims & Hers have gained 171% year to date, outperforming the industry's growth of 10.7%. Image Source: Zacks Investment Research HIMS' forward 12-month P/S of 5.6X is lower than the industry's average of 5.8X, but is higher than its three-year median of 2.3X. It carries a Value Score of D. Image Source: Zacks Investment Research The Zacks Consensus Estimate for HIMS' 2025 earnings per share suggests a 177.8% improvement from 2024. Image Source: Zacks Investment Research Hims & Hers stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today's Zacks #1 Rank stocks here. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Hims & Hers Health, Inc. (HIMS) : Free Stock Analysis Report LifeMD, Inc. (LFMD) : Free Stock Analysis Report Doximity, Inc. (DOCS) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research Error while retrieving data Sign in to access your portfolio Error while retrieving data Error while retrieving data Error while retrieving data Error while retrieving data

Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress
Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress

Yahoo

time30 minutes ago

  • Yahoo

Eledon Pharmaceuticals to Present Updated Clinical Data for Tegoprubart at World Transplant Congress

Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is one of the stocks under $10 to buy now. On July 17, Eledon Pharmaceuticals announced that updated clinical data from its ongoing open-label Phase 1b study of tegoprubart will be presented at the World Transplant Congress/WTC. The WTC will take place in San Francisco from August 2-6 this year. The oral presentation, titled 'Tegoprubart, an Anti-CD40L Antibody, for the Prevention of Rejection in Kidney Transplantation: An Ongoing Phase 1b Study,' will feature updated results from ~30 kidney transplant recipients. In addition to the oral presentation, Eledon Pharmaceuticals will sponsor a satellite symposium at the WTC titled: 'What Truly Defines Kidney Transplant Success: Early Rejection or Lasting Function?' A scientist in a laboratory holding a vial of medication developed by the biotechnology company. Furthermore, new preclinical data on tegoprubart's use for preventing rejection in non-human primates undergoing liver transplantation will be presented in a poster session. Eledon Pharmaceuticals Inc. (NASDAQ:ELDN) is a clinical-stage biotechnology company that uses its immunology expertise in targeting the CD40 Ligand/CD40L pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis/ALS. While we acknowledge the potential of ELDN as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the . READ NEXT: and . Disclosure: None. This article is originally published at Insider Monkey.

Michigan moms could soon have easier access to group prenatal care that's changing lives
Michigan moms could soon have easier access to group prenatal care that's changing lives

Yahoo

time32 minutes ago

  • Yahoo

Michigan moms could soon have easier access to group prenatal care that's changing lives

Picture this: instead of rushing through a prenatal appointment alone, you join a circle of eight or so expectant parents due around the same time. Over 90 relaxed minutes, you learn about stress management and breastfeeding, get individual check-ins from your provider, and build real relationships with other parents-to-be who actually get what you're going through. This is the heart of CenteringPregnancy, and if new legislation moves forward, moms across Michigan could soon have better access to this kind of support. On July 1, the Michigan Senate passed Senate Bills 414 and 415, which would require both private insurers and Medicaid to cover these group-based prenatal care programs. Related: New CDC data shows that more pregnant women are unable to access prenatal care Why it matters: the science of community prenatal care The idea is simple: you get your prenatal care in a group setting, alongside other pregnant people. But the impact goes way beyond the check-up. CenteringPregnancy helps normalize the experience of motherhood, offering emotional support and measurable health benefits. Studies have shown major benefits: A 33–47% drop in preterm births in randomized trials, with even stronger effects for Black mothers—a meaningful step toward addressing racial disparities in birth outcomes. A 40% reduction in postpartum depression symptoms at six months, according to a meta-analysis. For families already facing barriers to care, these improvements are life-changing. More than medical care: building a village Beyond the metrics, the emotional benefit of group prenatal care is hard to overstate. CenteringPregnancy creates space for parents to share fears, questions, and excitement with people on the same journey. It turns what can feel like a medical transaction into a shared rite of passage. For many moms, it means leaving appointments feeling empowered, informed, and less alone. It can also help detect mental health challenges earlier, improve breastfeeding success, and reduce feelings of isolation that so often accompany pregnancy and postpartum life. What the Michigan bills would change The two bills passed by the Senate aim to make this model a standard part of care—not just a nice-to-have pilot. Senate Bill 414 would require private insurers who already cover prenatal care to include group prenatal care in their plans. Senate Bill 415 would permanently secure Medicaid coverage for CenteringPregnancy in Michigan. (Medicaid already reimburses for it—but this law would ensure it stays that way.) By putting these requirements into law, the state would ensure consistent, widespread access, even if budgets or administrations change. Related: New York is officially the first state to mandate PTO for prenatal care A model the rest of the country should be watching Supporters of the legislation see Michigan as a potential national example. They argue that expanding CenteringPregnancy access is one of the simplest ways to improve maternal and infant health while also saving money on avoidable NICU stays and complications. For families, it represents a shift away from fragmented, rushed care toward a model that's relational, supportive, and proven to work. As a mom of five kids who was underwhelmed with the traditional prenatal care model, I'm excited about a healthcare system that doesn't just provide clinical insights, but also human connection. What's more intimate, life-transforming, and support-group worthy than bringing a new baby into the world? Sources: CenteringPregnancy: A model of group prenatal care. 2023. Centering Healthcare Institute. CenteringPregnancy: A model of group prenatal care. Group prenatal care reduces risk of preterm birth. October 2016. YaleNews. Group prenatal care reduces risk of preterm birth. Group prenatal care: A systematic review and meta-analysis of randomized controlled trials. November 2019. Obstetrics & Gynecology. Group prenatal care: A systematic review and meta-analysis of randomized controlled trials. SB 414 and SB 415. July 2024. Michigan Legislature. SB 414 and SB 415.

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into a world of global content with local flavor? Download Daily8 app today from your preferred app store and start exploring.
app-storeplay-store